X-11704

704

5. The compound of [any of] Claim[s 1-] 4 wherein R<sup>2</sup> is C=O.

-2-

- 6. The compound of [any of] Claim[s 1-] 5 wherein R<sup>3</sup> is Ar<sup>3</sup>.
- 7. The compound of [any of] Claim[s 1-] 6 wherein Ar<sup>3</sup> is 4-fluorophenyl.
- 8. The compound of [any of] Claim[s 1-6] 7 wherein Ar<sup>3</sup> is 4-fluorophenyl additionally mono- or disubstituted.
- 9. The compound of [any of] Claim[s 1-6] 8 wherein Ar<sup>3</sup> is selected from the group consisting of 2-iodo-4-fluorophenyl, 2-bromo-4-fluorophenyl, 2-chloro-4-fluorophenyl, 2,4-difluorophenyl, and 2-methyl-4-fluorophenyl, and 2,4,6-trifluorophenyl.
- 13. The method according to [either of] Claim[s] 11 [or Claim 12] where the mammal is a human.
- 16. The process [of any] of Claim[s] 14 [-15] wherein the source of the protecting group of step a) is trifluoroacetic anhydride.
- 17. The process [of any] of Claim[s] 14 [-16] wherein the source of the nitronium ion is ammonium nitrate.
- 18. (New Claim) The process of any of Claim 16 wherein the source of the nitronium ion is ammonium nitrate.
- 19. (New Claim) The method according to Claim 12 where the mammal is a human.
- 20. (New Claim) A method for treating migraine in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I:

X-11704

-3-

or a pharmaceutical acid addition salt thereof, where;

A is hydrogen, halo, -OR4, NH2, or -CF3;

R is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkynyl, or (C1-C6 alkyl)-Ar<sup>1</sup>;

 $R^1$  is -NH-R<sup>2</sup>-R<sup>3</sup>, hydroxy, -OSO<sub>2</sub>Ar<sup>2</sup>, or NH<sub>2</sub>;

Ar,  $Ar^{1}$ ,  $Ar^{2}$ ,  $Ar^{3}$ , and  $Ar^{4}$  are an optionally substituted phenyl or optionally substituted heteroaryl;

R2 is -CO-, -CS-, or -SO2-;

 $R^3$  is hydrogen, optionally substituted  $C_1$ - $C_6$  alkyl,  $Ar^3$ , -NR<sup>5</sup>R<sup>6</sup>, or OR<sup>5</sup>; provided R<sup>3</sup> is not hydrogen if R<sup>2</sup> is either -CS- or -SO<sub>2</sub>-;

 $\ensuremath{\mathsf{R}}^4$  is hydrogen, optionally substituted C1-C6 alkyl, or Ar; and

 ${
m R}^5$  and  ${
m R}^6$  are independently hydrogen, optionally substituted C<sub>1</sub>-C<sub>8</sub> alkyl, or Ar<sup>4</sup>; or R<sup>6</sup> and R<sup>5</sup> combine, together with the nitrogen atom to which they are attached, to form a pyrrolidine, piperidine, piperazine, 4-substituted piperazine, morpholine or thiomorpholine ring.

- 21. (New Claim) The method according to Claim 20 where the mammal is a human.
- 22. (New Claim) The compound of Claim 5 where A is hydrogen and R is methyl.
- 23. (New Claim) The compound of Claim 6 where A is hydrogen and R is methyl.